biotech

N-Acetylglucosamine Inhibits Multiple Sclerosis, Type 1 Diabetes

Filed in archive Drugs, Vaccines and Therapeutics , Food and Agriculture on May 21, 2007

N-Acetylglucosamine Inhibits Multiple Sclerosis, Type 1 Diabetes
A glucosamine-like dietary supplement, N-acetylglucosamine (GlcNAc), has been found to suppress the damaging autoimmune response observed in multiple sclerosis and type 1 diabetes mellitus.
In studies on mice, Dr. Michael Demetriou and colleagues with the UC Irvine Center for Immunology found that N-acetylglucosamine (GlcNAc), which is similar but more effective than the widely available glucosamine, inhibited the growth and function of abnormal T-cells that incorrectly direct the immune system to attack specific tissues in the body, such as brain myelin in MS and insulin-producing cells of the pancreas in diabetes.

Together with a recent study on the use of GlcNAc in the treatment of treatment-resistant autoimmune inflammatory bowel disease, these findings point to the use of metabolic therapy using dietary supplements such as GlcNAc for treating autoimmune diseases.

More details from UC Irvine.


Permalink: N-Acetylglucosamine Inhibits Multiple Sclerosis, Type 1 Diabetes

Tags: multiple+sclerosis  diabetes  acetylglucosamine  dietary+supplement  autoimmune+disease  biotech  biotech+ 

Vote for N-Acetylglucosamine Inhibits Multiple Sclerosis, Type 1 Diabetes:

  • Currently 9.08/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 9.08 out of 12 vote(s) cast.
 
Share It
RSSrss
Google google
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Most Popular   Best of   Biotech Hubs and Facilities   Biotech/Science Blogs   Corporate and Industrial News   Diagnostics, Methodologies and Instrumentation   Did you know   Drugs, Vaccines and Therapeutics   Energy, Environment and Ecology   Food and Agriculture   Gene Therapy   Genomics, Proteomics and Bioinformatics   Information About   Meetings and Other Events   Microbiology   Misc   Nanomedicine   Other Biotechnology News   Patents and Intellectual Property Rights   Quick introduction   Stem Cells